Patents Examined by Erinne R Dabkowski
-
Patent number: 10208085Abstract: The present invention relates to decoy peptide or polypeptide consisting of a peptide sequence represented by the following Formula I: X1-Ala-X2—X3-Ile-Glu-X4 (I). It is noteworthy that the decoy peptide or polypeptide of the present invention significantly elevates phosphorylation levels of PLB by inhibiting PP1-mediated dephosphorylation. In addition, the decoy peptide or polypeptide provides cardio-protective effects by restoring of SERCA2a activity and inotropic effect of enhancing myocardial contractility. The present invention will contribute greatly to the prevention or treatment of diseases associated with PLB.Type: GrantFiled: July 5, 2013Date of Patent: February 19, 2019Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Woo Jin Park, Roger J. Hajjar, Jae Gyun Oh
-
Patent number: 10196432Abstract: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.Type: GrantFiled: September 5, 2006Date of Patent: February 5, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventor: Jörn Dengiel
-
Patent number: 10174081Abstract: Materials and methods for making and using cationic anti-microbial peptides (CAMPs), and compositions containing such peptides.Type: GrantFiled: April 20, 2012Date of Patent: January 8, 2019Assignee: George Mason Research Foundation, Inc.Inventors: Barney Bishop, Monique van Hoek
-
Patent number: 10167322Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. In particular, the present invention relates to albumin binding polypeptides which have a high resistance to proteolytic cleavage and therapeutic use thereof. The disclosure provides an albumin binding polypeptide comprising an albumin binding motif, which motif consists of the amino acid sequence (SEQ?ID?NO.?1782) GXASDX5YKX8X9I?X11X12AX14TVEGVX20?ALX23X24X25ILX28X29XB.Type: GrantFiled: December 19, 2014Date of Patent: January 1, 2019Assignee: AFFIBODY ABInventors: Caroline Ekblad, Fredrik Frejd, Joel Lindgren, Amelie Eriksson Karlström
-
Patent number: 10155792Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. In particular, the present invention relates to albumin binding polypeptides which have a high resistance to enzymatic cleavage. The disclosure provides an albumin binding polypeptide comprising an albumin binding motif, which motif consists of the amino acid sequence GVSDFYKKLI XaKAKTVEGVE ALKXbXcI (SEQ ID NO:29).Type: GrantFiled: September 25, 2013Date of Patent: December 18, 2018Assignee: AFFIBODY ABInventors: Caroline Ekblad, Joachim Feldwisch, Kyong-Hoon Ahn
-
Patent number: 10138284Abstract: An insulin analog comprises a B-chain polypeptide containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. A proinsulin analog or single-chain insulin analog containing a B domain containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. The analog may be an analog of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analog is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions.Type: GrantFiled: September 27, 2016Date of Patent: November 27, 2018Assignee: Case Western Reserve UniversityInventor: Michael A. Weiss
-
Patent number: 10125184Abstract: Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods.Type: GrantFiled: November 25, 2015Date of Patent: November 13, 2018Assignees: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF SOUTH CAROLINAInventors: Tony Tianyi Wang, Shufeng Liu, Fan Daping
-
Patent number: 10123985Abstract: Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.Type: GrantFiled: June 8, 2016Date of Patent: November 13, 2018Assignees: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Howard Hughes Medical InstituteInventors: David M. Sabatini, Kivanc Birsoy, Matthew George Vander Heiden, Lucas Bryan Sullivan, Dan Yi Gui
-
Patent number: 10118949Abstract: The present invention relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for the treatment of disease in mammals including humans.Type: GrantFiled: November 24, 2014Date of Patent: November 6, 2018Assignee: AFFIBODY ABInventors: Lars Abrahmsén, Andreas Jonsson, Jakob Dogan, Per-Åke Nygren
-
Patent number: 10106597Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: GrantFiled: December 30, 2016Date of Patent: October 23, 2018Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz
-
Patent number: 10106590Abstract: Provided herein are polypeptides containing stabilized BH4 domains of BCL-2 family proteins that are capable of binding and/or inactivating and/or modulating BAX protein, and/or its close homologs BAK and BOK, and/or other physiological BH4 targets. Also provided are compositions containing these polypeptides and methods of treating cytotoxic diseases that include administering to a subject one of the polypeptides.Type: GrantFiled: March 14, 2014Date of Patent: October 23, 2018Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. Walensky, Michelle L. Stewart, Lauren Barclay
-
Patent number: 10087229Abstract: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-Aib-Glu-Gly-Thr-alphaMePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 (I) wherein each symbol is as defined herein.Type: GrantFiled: May 27, 2014Date of Patent: October 2, 2018Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Taiji Asami, Ayumu Niida
-
Patent number: 10081657Abstract: The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, in which the biosynthetic random coil polypeptide, the biosynthetic random coil polypeptide segment, or the biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein the amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. The at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) constituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or conjugates are described.Type: GrantFiled: November 12, 2015Date of Patent: September 25, 2018Assignees: TECHNISCHE UNIVERSITAT MUNCHEN, XL-PROTEIN GMBHInventors: Arne Skerra, Uli Binder, Martin Schlapschy
-
Patent number: 10065995Abstract: An object of the present invention is to provide a technique to create novel engineered protein ligands that, when immobilized through a lysine residue (its side chain ?-amino group) which allows for efficient immobilization to a carrier, show the optimum binding capacity and binding efficiency to a target molecule. The present invention provides an engineered protein having a sequence obtained by replacing all the lysine residues in Protein A, which is the most typical protein ligand, with other amino acids, and adding lysine at a terminal; and an affinity separation matrix in which such an engineered protein is immobilized on a water-insoluble carrier by reductive amination or the like. This affinity separation matrix is characterized by its high binding capacity to a target molecule even when the immobilized amount of the ligand is small.Type: GrantFiled: March 26, 2012Date of Patent: September 4, 2018Assignee: KANEKA CORPORATIONInventors: Shinichi Yoshida, Dai Murata, Shunichi Taira
-
Patent number: 10064915Abstract: There is provided a fusion protein comprising albumin and retinol-binding protein (RBP), which can be used for preventing or treating fibrotic diseases. The fusion protein, in which albumin and RBP are bound together, is incorporated into stellate cells and induces phenotypic reversion from myofibroblast-like cells to quiescent fat-storing phenotype. Therefore, the fusion protein can be effectively used in preventing or treating fibrotic diseases occurring in the liver, pancreas, lung, or other organs.Type: GrantFiled: June 6, 2017Date of Patent: September 4, 2018Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventor: Jun Seo Oh
-
Patent number: 10064914Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.Type: GrantFiled: May 4, 2016Date of Patent: September 4, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Pinchas Cohen, Changhan Lee
-
Patent number: 10059742Abstract: The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof.Type: GrantFiled: July 20, 2016Date of Patent: August 28, 2018Assignee: The Governing Council of the University of TorontoInventor: Paulo Koeberle
-
Patent number: 10023623Abstract: The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.Type: GrantFiled: September 1, 2015Date of Patent: July 17, 2018Assignee: Alkermes, Inc.Inventors: Juan Alvarez, Jean Chamoun, Heather C. Losey
-
Patent number: 10017551Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.Type: GrantFiled: March 14, 2014Date of Patent: July 10, 2018Assignee: The Regents of the University of CaliforniaInventors: John K. Bielicki, Jan Johansson, Waleed Danho
-
Patent number: 10011634Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.Type: GrantFiled: September 2, 2015Date of Patent: July 3, 2018Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: Xiaoping Du